Onco-Innovations Subsidiary Explores Real-World Relevance of Lung Cancer Trials

Onco-Innovations Limited's subsidiary, Inka Health, has published a study addressing the applicability of clinical trial results to diverse real-world lung cancer populations. Titled "Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations," the study appears in medRxiv. It features Lung-MAP S1400I as a case study, yielding predictive results closely aligning with actual patient outcomes.

By utilizing advanced modeling and external clinical knowledge, the study improves the pertinence of clinical trials to daily practice, offering insights for Inka's SynoGraph platform. This approach significantly enhances trial design and the understanding of broader patient populations.

These findings highlight the potential to bridge gaps between trial outcomes and practical applications, thereby supporting improvements in clinical decision-making, regulation, and patient access to treatments globally. Co-authored by Dr. Vivek Subbiah, the study underscores the importance of inclusive drug development methodologies.